E
Emanuele Palescandolo
Researcher at Harvard University
Publications - 23
Citations - 8987
Emanuele Palescandolo is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & KRAS. The author has an hindex of 18, co-authored 23 publications receiving 7603 citations. Previous affiliations of Emanuele Palescandolo include Dana Corporation & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina,Giordano Caponigro,Nicolas Stransky,Kavitha Venkatesan,Adam A. Margolin,Adam A. Margolin,Sungjoon Kim,Christine D. Wilson,Joseph Lehar,Gregory V. Kryukov,Dmitriy Sonkin,Anupama Reddy,Manway Liu,Lauren Murray,Michael F. Berger,Michael F. Berger,John Monahan,Paula Morais,Jodi Meltzer,Adam Korejwa,Judit Jané-Valbuena,Judit Jané-Valbuena,Felipa A. Mapa,Joseph Thibault,Eva Bric-Furlong,Pichai Raman,Aaron Shipway,Ingo H. Engels,Jill Cheng,Guoying K. Yu,Jianjun Yu,Peter Aspesi,Melanie de Silva,Kalpana Jagtap,Michael D. Jones,Li Wang,Charlie Hatton,Emanuele Palescandolo,Supriya Gupta,Scott Mahan,Carrie Sougnez,Robert C. Onofrio,Ted Liefeld,Laura E. MacConaill,Wendy Winckler,Michael R. Reich,Nanxin Li,Jill P. Mesirov,Stacey Gabriel,Gad Getz,Kristin G. Ardlie,Vivien W. Chan,Vic E. Myer,Barbara L. Weber,Jeffrey A. Porter,Markus Warmuth,Peter Finan,Jennifer L. Harris,Matthew Meyerson,Matthew Meyerson,Todd R. Golub,Michael Morrissey,William R. Sellers,Robert Schlegel,Levi A. Garraway,Levi A. Garraway +65 more
TL;DR: The results indicate that large, annotated cell-line collections may help to enable preclinical stratification schemata for anticancer agents and the generation of genetic predictions of drug response in the preclinical setting and their incorporation into cancer clinical trial design could speed the emergence of ‘personalized’ therapeutic regimens.
Journal ArticleDOI
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations
Priscilla K. Brastianos,Peleg M. Horowitz,Sandro Santagata,Sandro Santagata,Robert T. Jones,Aaron McKenna,Gad Getz,Keith L. Ligon,Keith L. Ligon,Emanuele Palescandolo,Paul Van Hummelen,Matthew D. Ducar,Alina Raza,Ashwini Sunkavalli,Laura E. MacConaill,Anat Stemmer-Rachamimov,David N. Louis,William C. Hahn,Ian F. Dunn,Ian F. Dunn,Ian F. Dunn,Rameen Beroukhim +21 more
TL;DR: The spectrum of genetic alterations in meningiomas is defined and potential therapeutic targets are identified to identify and validate somatic genetic alterations.
Journal ArticleDOI
RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
Patrick A. Oberholzer,Damien Kee,Damien Kee,Piotr Dziunycz,Antje Sucker,Nyam Kamsu-Kom,Robert T. Jones,Christine Roden,Clinton J. Chalk,Kristin G. Ardlie,Emanuele Palescandolo,Adriano Piris,Laura E. MacConaill,Laura E. MacConaill,Caroline Robert,Günther F.L. Hofbauer,Grant A. McArthur,Dirk Schadendorf,Levi A. Garraway +18 more
TL;DR: Squamous cell tumors from patients treated with an RAF inhibitor have a distinct mutational profile that supports a mechanism of therapy-induced tumorigenesis in RAS-primed cells, and Conceivably, cotargeting of MEK together with RAF may reduce or prevent formation of these tumors.
Journal ArticleDOI
Erratum: Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity (Nature (2012) 483 7391 (603-607))
Jordi Barretina,Jordi Barretina,Jordi Barretina,Giordano Caponigro,Nicolas Stransky,Kavitha Venkatesan,Adam A. Margolin,Sungjoon Kim,Christine D. Wilson,Joseph Lehar,Gregory V. Kryukov,Dmitriy Sonkin,Anupama Reddy,Manway Liu,Lauren Murray,Michael F. Berger,Michael F. Berger,John Monahan,Paula Morais,Jodi Meltzer,Adam Korejwa,Judit Jané-Valbuena,Judit Jané-Valbuena,Felipa A. Mapa,Joseph Thibault,Eva Bric-Furlong,Pichai Raman,Aaron Shipway,Ingo H. Engels,Jill Cheng,Guoying K. Yu,Jianjun Yu,Peter Aspesi,Melanie de Silva,Kalpana Jagtap,Michael D. Jones,Li Wang,Charlie Hatton,Emanuele Palescandolo,Supriya Gupta,Scott Mahan,Carrie Sougnez,Robert C. Onofrio,Ted Liefeld,Laura E. MacConaill,Wendy Winckler,Michael R. Reich,Nanxin Li,Jill P. Mesirov,Stacey Gabriel,Gad Getz,Kristin G. Ardlie,Vivien W. Chan,Vic E. Myer,Barbara L. Weber,Jeffrey A. Porter,Markus Warmuth,Peter Finan,Jennifer L. Harris,Matthew Meyerson,Matthew Meyerson,Todd R. Golub,Michael Morrissey,William R. Sellers,Robert Schlegel,Levi A. Garraway,Levi A. Garraway +66 more
TL;DR: Jordi Barretina, Giordano Caponigro, Nicolas Stransky, Kavitha Venkatesan, Adam A. Golub, Michael P. Morais, Jodi Meltzer, Judit Jané-Valbuena, Felipa A. Mapa, Joseph Thibault, Eva Bric-Furlong, Pichai Raman, Aaron Shipway, Ingo H. Engels, Jill Cheng, Guoying K. Yu
Journal ArticleDOI
Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer
Toshiro Migita,Stacey Ruiz,Alessandro Fornari,Michelangelo Fiorentino,Carmen Priolo,Giorgia Zadra,Fumika Inazuka,Chiara Grisanzio,Emanuele Palescandolo,Eyoung Shin,Christopher Fiore,Wanling Xie,Andrew L. Kung,Phillip G. Febbo,Aravind Subramanian,Lorelei A. Mucci,Jing Ma,Sabina Signoretti,Meir J. Stampfer,William C. Hahn,Stephen P. Finn,Massimo Loda +21 more
TL;DR: FASN can act as a prostate cancer oncogene in the presence of AR and that FASN exerts its oncogenic effect by inhibiting the intrinsic pathway of apoptosis by using the least squares means procedure.